Bilateral Optic Neuritis Treated with Intravenous Corticosteroid

Muhammad H

Department of Ophthalmology, Andalas University, M. Djamil Hospital Padang, Indonesia

*Corresponding author: Muhammad Hidayat, Department of Ophthalmology, Andalas University, M. Djamil Hospital Padang, Indonesia, Tel: +62 811666309; E-mail: mhsptmi22@yahoo.com

Receive date: May 23, 2018; Accepted date: October 09, 2018; Published date: October 11, 2018

Abstract

Introduction: Optic neuritis is a term used to refer an inflammation of the optic nerve. Bilateral optic neuritis in adults has been considered rare particularly in individuals without known systemic inflammatory or autoimmune disorders.

Purpose: To describe cases of acute bilateral optic neuritis in adult treated with intravenous corticosteroid in M. Djamil Hospital, Padang, Indonesia.

Method: We performed a retrospective study review of medical records from patients referred to neuro-ophthalmology clinic in M. Djamil Hospital with acute bilateral optic neuritis from January 2016 to April 2017. Exclusion criteria included previous multiple sclerosis or myelopathy, known systemic disorders or medications associated with optic neuropathy, uveitis, or neoplasm. Patients received intravenous methylprednisolone followed by tapering oral metilprednisolone. Visual acuity, visual fields, ophthalmoscopy finding, and neurological evaluation were recorded at baseline and at 1 month or 3 months.

Result: Nine patients of 4 men and 5 women, with an age range of 21-45 years old, had bilateral decreased vision, 6 with pain on eye movement. All patients had normal neurological evaluations, with visual acuity ranging from finger counting to hand movement and variety of visual field pattern. Both optic nerves showed abnormal ophthalmoscopy finding. After corticosteroid therapy for average 2 weeks, all patients show improvement in visual acuity, visual field, and ophthalmoscopy finding. No patient developed a neurological problem during the follow up with a mean of 3 months.

Conclusion: Idiopathic acute bilateral optic neuritis rarely occurs in adults. Corticosteroid therapy shows good visual outcome.

Keywords: Bilateral optic neuritis; Corticosteroid therapy

Introduction

Optical neuritis involves the inflammation, disintegration, and demyelination of the optic nerve and might be unilateral or bilateral, typical or atypical. Typical optic neuritis may occur alone or together with multiple sclerosis, whereas atypical optic neuritis is not associated with multiple sclerosis.

Clinical manifestations of optic neuritis are moderate to severe acute-to-severe, worsening in hours to days. Orbital pain at the time of movement is one of the typical symptoms of optic neuritis, caused by stimulation of the trigeminal nerve due to the inflammatory process. Color vision disorder (dyscromatopsia) is common in optic neuritis and is associated with the duration of the disease.

Blue-yellow vision impairment often occurs in the acute phase and red-green defects often occur after 6 months. The decrease in contrast sensitivity is usually the earliest symptom when compared with decreased vision. In optic neuritis, visual field defects may vary, but the most common feature is the central scotoma. Fundoscopic examination of optic neuritis shows elevation and hyperemia of the optic disc. In retrobulbar optic neuritis, the fundoscopic image will appear normal. Relative Afferent Pupillary Defects (RAPD) do not appear in bilateral cases [1].

Bilateral optic neuritis arises as a sudden decrease in bilateral vision. Bilateral optic neuritis is usually thought to be only affecting children, often caused by viral infections, and not related to multiple sclerosis. In contrast, adult's bilateral optic neuritis is rare especially in individuals without systemic inflammation or autoimmune disorders. Most cases of bilateral optic neuritis occur non-simultaneously (within 3 months), while about 7% of bilateral cases occur simultaneously [2]. Magnetic Resonance Imaging (MRI) examination usually shows bilateral enhancement in the intra orbital optic nerve. Other investigations that can be performed are Computed tomography (CT) scan and cerebrospinal fluid examination in suspected cases of infection (to assess the presence of cells).

Visual recovery in bilateral optical neuritis is important regardless of treatment. Optic neuritis is known to be highly responsive to high-dose corticosteroids. Methylprednisolone 250 mg intravenously given every 6 hrs for 3 days (total 12 doses) and followed by tapering dose 0.8 mg/kg/day for 11 days.

Some reports illustrate the course, recovery, and outcome (visual acuity) after optic neuritis patients are treated with high-dose corticosteroids. We recently noted an increase in the number of adult
patients without systemic autoimmune or neurologic diseases diagnosed with bilateral optical neuritis by documenting the patients’ clinical profile [3]. The effectiveness of corticosteroid therapy, visual recovery time, visual outcome and neurologic symptoms were followed up for 3 months.

**Methods**

We conducted a retrospective study of patients diagnosed with bilateral optical neuritis from January 2016 to April 2017. Patients were included if they experienced symptoms such as acute bilateral dysfunction diagnosed by optic nerve abnormalities, complete ophthalmological examination, laboratory analysis and brain CT scan were performed at the time of symptoms appear, and follow up for at least 3 months [4]. Exclusion criteria includes previously known multiple sclerosis, previous optic neuritis or myelopathy, systemic abnormalities known to be associated with optic neuropathy, use of drugs associated with toxic optic neuropathy, previous history of uveitis, systemic neoplasms, or known intracranial abnormalities.

Visual acuity examination is done for each eye on arrival and at 3 days of follow up, 2 weeks, and 3 months [5]. Visual acuity is assessed by using Snellen chart. Perimetry is performed by analysis of outcome measures. Color vision impairment was assessed using the dyschromatopsia, complete Farnsworth 28 Hue color plate.

<table>
<thead>
<tr>
<th>S.No</th>
<th>Age</th>
<th>Sex</th>
<th>Visual Activity before Treatment</th>
<th>Visual Activity after 3 days treatment</th>
<th>Visual Activity after 2 weeks treatment</th>
<th>Visual Activity after 3 months treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>RE</td>
<td>LE</td>
<td>RE</td>
<td>LE</td>
</tr>
<tr>
<td>1</td>
<td>30</td>
<td>F</td>
<td>3/60</td>
<td>5/60</td>
<td>6/9</td>
<td>1/60</td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>F</td>
<td>1/300</td>
<td>4/60</td>
<td>6/21</td>
<td>6/9</td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>F</td>
<td>1/300</td>
<td>1/60</td>
<td>1/60</td>
<td>6/6f</td>
</tr>
<tr>
<td>4</td>
<td>30</td>
<td>F</td>
<td>1/60</td>
<td>3/60</td>
<td>6/9</td>
<td>6/7.5</td>
</tr>
<tr>
<td>5</td>
<td>39</td>
<td>M</td>
<td>2/60</td>
<td>3/60</td>
<td>6/6f</td>
<td>6/12</td>
</tr>
<tr>
<td>6</td>
<td>23</td>
<td>M</td>
<td>2/60</td>
<td>2/60</td>
<td>6/7.5</td>
<td>6/7.5</td>
</tr>
<tr>
<td>7</td>
<td>45</td>
<td>M</td>
<td>1/300</td>
<td>2/60</td>
<td>6/12</td>
<td>6/6f</td>
</tr>
<tr>
<td>8</td>
<td>43</td>
<td>F</td>
<td>1/300</td>
<td>1/60</td>
<td>6/7.5</td>
<td>6/60</td>
</tr>
<tr>
<td>9</td>
<td>35</td>
<td>M</td>
<td>1/60</td>
<td>1/300</td>
<td>6/6f</td>
<td>6/9</td>
</tr>
</tbody>
</table>

F: Female count; M: Male count

**Table 1**: Demographic and presentation evaluations.

An ophthalmologic examination (visual acuity, color vision, and contrast sensitivity) was continued at 3 months of follow up for all patients [9,10]. Most patients experience a sharp increase in vision to near normal, as well as color vision and contrast sensitivity. One patient, case 3, did not experience a sharp increase in vision because the patient came too late and the visual acuity decrease was permanent. None of the patients had symptoms of ongoing neurological dysfunction and a normal clinical neurologic examination at the last evaluation, which was performed for 3 months.

**Discussion**

All patients who met the inclusion criteria shows that female patients were more than men, with a ratio of 2:1. This is related to...
some previous studies which found that optical neuritis is more common in women. Acute vision loss is the main clinical symptom in all patients, according to typical symptoms of optic neuritis. In addition, orbital pain when moved is also a symptom of the most complained by the patient. Color vision and contrast sensitivity vary with all patients.

Although the presentation and severity of visual impairment in cases of bilateral optical neuritis is quite dramatic, the visual recovery is excellent in almost all patients except in one patient. A marked asymmetric decrease of visual acuity occurs in one patient (case 2). Examination of orbital CT scans and brain CT scans are within normal limits in all patients.

The absence of RAPD in almost all patients with bilateral optic neuritis results from bilateral afferent dysfunction. Cases with RAPD may be due to an unequal dysfunction between the affected optic nerve. The etiology of infection, usually virus, is associated with bilateral optical neuritis in children and unilateral demyelination optic neuritis, but systemic processes are not generally present in our patients.

Corticosteroids are the first choice in the management of bilateral optical neuritis. All patients were treated with high-dose corticosteroids based on Optic Neuritis Treatment Trial (ONTT). Based on the severity of vision loss and the profile of corticosteroid side effects, we chose to treat patients intravenously followed by oral corticosteroids. Our findings support previous reports suggesting that bilateral optical neuropathy suspected due to inflammatory processes, has a generally good prognosis and is responsive to high-dose corticosteroid therapy.

Conclusion

Bilateral optic neuritis without myelopathy occurs more frequently in adults than previously thought. Diagnosis and therapeutic approach in patients with symptoms and signs of optic neuritis should be performed thoroughly in both patients with and without systemic abnormalities or previous autoimmune disorders. Bilateral visual impairment improves with corticosteroids without additional immunomodulatory therapy. The sequelae of neurological abnormality or recurrent visual loss may occur, so follow up should be 6 to 12 months. Idiopathic acute bilateral optic neuritis is a rare case that needs further study, especially its treatment with corticosteroid therapy to improve visual outcome.

References